Cargando…
Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial
OBJECTIVE: To observe the effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome(PCOS). METHODS: A total of 64 overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomly ass...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10280986/ https://www.ncbi.nlm.nih.gov/pubmed/37347114 http://dx.doi.org/10.3389/fendo.2023.1156521 |
_version_ | 1785060920150458368 |
---|---|
author | Wen, Qing Fang, Song Liang, Yanjing Tian, Yuting Chen, Yiding Yuan, Jun Chen, Qiu |
author_facet | Wen, Qing Fang, Song Liang, Yanjing Tian, Yuting Chen, Yiding Yuan, Jun Chen, Qiu |
author_sort | Wen, Qing |
collection | PubMed |
description | OBJECTIVE: To observe the effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome(PCOS). METHODS: A total of 64 overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomly assigned to metformin(MET) 850 mg twice a day(BID) or combined MET 850 mg BID with beinaglutide (COMB) starting at 0.1mg three times a day(TID)and increasing to 0.2mg TID two weeks later. The main endpoints were changes in anthropometric measurements of obesity. Glucose and lipid metabolic, gonadal profiles, and antral follicle count changes as secondary outcomes were also observed. RESULTS: 60(93.75%) patients completed the study. In terms of lowering weight, body mass index (BMI),waist circumference(WC) and waist to height ratio(WHtR), COMB treatment outperformed MET monotherapy. Subjects in the COMB arm lost weight 4.54±3.16kg compared with a 2.47±3.59kg loss in the MET arm. In the COMB group, BMI,WC and WHtR were reduced significantly compared with that in the MET group, respectively. COMB therapy is also more favorable in the reduction of fasting insulin(FINS), total testosterone(TT), and homeostasis model assessment–insulin resistance(HOMA-IR) when compared to MET therapy. Antral follicle count and ovarian volume were non-significantly changed in both groups.The most frequent side effects in both groups were mild and moderate digestive symptoms. Itching and induration at the injection site were reported with COMB treatment. CONCLUSION: Short-term combined treatment with beinaglutide and metformin appears superior to metformin monotherapy in lowering body weight, BMI, WC,WHtR and improving insulin sensitivity and androgen excess in women with PCOS and obesity, with tolerable adverse events. CLINICAL TRIAL REGISTRATION: https://www.chictr.org.cn/listbycreater.aspx, identifier ChiCTR2000033741. |
format | Online Article Text |
id | pubmed-10280986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102809862023-06-21 Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial Wen, Qing Fang, Song Liang, Yanjing Tian, Yuting Chen, Yiding Yuan, Jun Chen, Qiu Front Endocrinol (Lausanne) Endocrinology OBJECTIVE: To observe the effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome(PCOS). METHODS: A total of 64 overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomly assigned to metformin(MET) 850 mg twice a day(BID) or combined MET 850 mg BID with beinaglutide (COMB) starting at 0.1mg three times a day(TID)and increasing to 0.2mg TID two weeks later. The main endpoints were changes in anthropometric measurements of obesity. Glucose and lipid metabolic, gonadal profiles, and antral follicle count changes as secondary outcomes were also observed. RESULTS: 60(93.75%) patients completed the study. In terms of lowering weight, body mass index (BMI),waist circumference(WC) and waist to height ratio(WHtR), COMB treatment outperformed MET monotherapy. Subjects in the COMB arm lost weight 4.54±3.16kg compared with a 2.47±3.59kg loss in the MET arm. In the COMB group, BMI,WC and WHtR were reduced significantly compared with that in the MET group, respectively. COMB therapy is also more favorable in the reduction of fasting insulin(FINS), total testosterone(TT), and homeostasis model assessment–insulin resistance(HOMA-IR) when compared to MET therapy. Antral follicle count and ovarian volume were non-significantly changed in both groups.The most frequent side effects in both groups were mild and moderate digestive symptoms. Itching and induration at the injection site were reported with COMB treatment. CONCLUSION: Short-term combined treatment with beinaglutide and metformin appears superior to metformin monotherapy in lowering body weight, BMI, WC,WHtR and improving insulin sensitivity and androgen excess in women with PCOS and obesity, with tolerable adverse events. CLINICAL TRIAL REGISTRATION: https://www.chictr.org.cn/listbycreater.aspx, identifier ChiCTR2000033741. Frontiers Media S.A. 2023-06-06 /pmc/articles/PMC10280986/ /pubmed/37347114 http://dx.doi.org/10.3389/fendo.2023.1156521 Text en Copyright © 2023 Wen, Fang, Liang, Tian, Chen, Yuan and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Wen, Qing Fang, Song Liang, Yanjing Tian, Yuting Chen, Yiding Yuan, Jun Chen, Qiu Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial |
title | Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial |
title_full | Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial |
title_fullStr | Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial |
title_full_unstemmed | Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial |
title_short | Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial |
title_sort | short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10280986/ https://www.ncbi.nlm.nih.gov/pubmed/37347114 http://dx.doi.org/10.3389/fendo.2023.1156521 |
work_keys_str_mv | AT wenqing shorttermeffectofbeinaglutidecombinedwithmetforminversusmetforminaloneonweightlossandmetabolicprofilesinobesepatientswithpolycysticovarysyndromeapilotrandomizedtrial AT fangsong shorttermeffectofbeinaglutidecombinedwithmetforminversusmetforminaloneonweightlossandmetabolicprofilesinobesepatientswithpolycysticovarysyndromeapilotrandomizedtrial AT liangyanjing shorttermeffectofbeinaglutidecombinedwithmetforminversusmetforminaloneonweightlossandmetabolicprofilesinobesepatientswithpolycysticovarysyndromeapilotrandomizedtrial AT tianyuting shorttermeffectofbeinaglutidecombinedwithmetforminversusmetforminaloneonweightlossandmetabolicprofilesinobesepatientswithpolycysticovarysyndromeapilotrandomizedtrial AT chenyiding shorttermeffectofbeinaglutidecombinedwithmetforminversusmetforminaloneonweightlossandmetabolicprofilesinobesepatientswithpolycysticovarysyndromeapilotrandomizedtrial AT yuanjun shorttermeffectofbeinaglutidecombinedwithmetforminversusmetforminaloneonweightlossandmetabolicprofilesinobesepatientswithpolycysticovarysyndromeapilotrandomizedtrial AT chenqiu shorttermeffectofbeinaglutidecombinedwithmetforminversusmetforminaloneonweightlossandmetabolicprofilesinobesepatientswithpolycysticovarysyndromeapilotrandomizedtrial |